000			01588 a2200397 4500
005			20250514024653.0
264		0	_c20020308
008			200203s 0 0 eng d
022			_a0160-6689
024	7		_a10.4088/jcp.v63n0202 _2doi
040			_aNLM _beng _cNLM
100	1		_aThase, Michael E
245	0	0	_aWhat role do atypical antipsychotic drugs have in treatment-resistant depression? _h[electronic resource]
260			_bThe Journal of clinical psychiatry _cFeb 2002
300			_a95-103 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAntidepressive Agents, Tricyclic _xtherapeutic use
650	0	4	_aAntipsychotic Agents _xadverse effects
650	0	4	_aControlled Clinical Trials as Topic
650	0	4	_aDepressive Disorder _xdrug therapy
650	0	4	_aDopamine Agonists _xtherapeutic use
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDyskinesia, Drug-Induced _xetiology
650	0	4	_aHumans
650	0	4	_aHyperprolactinemia _xchemically induced
650	0	4	_aLithium _xtherapeutic use
650	0	4	_aPatient Compliance
650	0	4	_aSelective Serotonin Reuptake Inhibitors _xtherapeutic use
650	0	4	_aTreatment Outcome
650	0	4	_aTriiodothyronine _xtherapeutic use
650	0	4	_aWeight Gain _xdrug effects
773	0		_tThe Journal of clinical psychiatry _gvol. 63 _gno. 2 _gp. 95-103
856	4	0	_uhttps://doi.org/10.4088/jcp.v63n0202 _zAvailable from publisher's website
999			_c11781503 _d11781503